+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Chronic Lower Back Pain (CLBP) - Epidemiology Forecast - 2034

  • PDF Icon

    Report

  • 146 Pages
  • December 2024
  • Region: Global
  • DelveInsight
  • ID: 5010957
UP TO OFF until Dec 31st 2024

Key Highlights

  • The analyst projects that the total diagnosed prevalent of Chronic Lower Back Pain cases in 7MM were approximately 67 million in 2022 and these cases are going to increase because of changes in psychosocial and physical work demands, risk factors for LBP (2023-2034).
  • According to analysis, the total number of diagnosed prevalent cases of CLBP in the US was found to be nearly 30 million in 2022 and is estimated to increase with a significant CAGR throughout the forecast period.
  • In 2022, the total number of diagnosed prevalent cases of CLBP was approximately 27 million in EU4 and the UK, which is anticipated to increase during the study period [2020-2034].
  • According to estimates, Japan accounted for nearly 16% of the total number of diagnosed prevalent cases of CLBP in the 7MM in 2022.
The “Chronic Lower Back Pain (CLBP) - Epidemiology - 2034” report delivers an in-depth understanding of Chronic Lower Back Pain, historical and forecasted epidemiology of Chronic Lower Back Pain in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

  • The United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan

Study Period: 2020-2034

Chronic Lower Back Pain Disease Understanding

Chronic Lower Back Pain Overview

Chronic Lower Back Pain (CLBP) is sudden damage to the brain caused by a blow or jolt to the head. Common causes include car or motorcycle crashes, falls, sports injuries, and assaults. It is evident that many people dealing with persistent chronic pain also have feelings of anxiety or depression, which worsen their CLBP. A valuable approach involves screening for these psychological conditions and providing patients with antidepressants or counseling when there is a psychological component to their pain syndrome.

Chronic Lower Back Pain Diagnosis

Despite ongoing advancements in medical diagnostic techniques, the majority of back pain cases still lack a definitive diagnosis of the underlying source. Many patients undergo inappropriate treatments without a clear understanding of the origin of their back pain, leading to significant financial expenditures on diagnostic evaluations that often fail to identify the precise cause. This persistent challenge highlights an unmet need for more effective and accurate diagnostic tools to discern the physical and non-physical sources of back pain, ultimately improving the targeted and efficient management of this common health issue.

Chronic Lower Back Pain Epidemiology

As the market is derived using the patient-based model, the Chronic Lower Back Pain epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of CLBP, Diagnosed Prevalent Cases of CLBP, Gender-specific Diagnosed Prevalent Cases of CLBP, and Age-specific Diagnosed Prevalent Cases of CLBP in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

According to estimations, approximately 80 million prevalent cases of CLBP were found in 2022 in the 7MM.

The United States exhibited the highest diagnosed prevalent population of CLBP, as compared to other 7MM countries. As per estimations, the total number of diagnosed prevalent cases with Chronic Lower Back Pain in the US was around 30 million in 2022 and is projected to increase during the forecast period owing to the increasing prevalent population.

According to estimates, the Diagnosed Prevalent Cases of CLBP in EU4 and the UK were found to be 27 million in 2022. Throughout the study period, it is anticipated that there will be a substantial increase in cases for all contributing countries, except for Germany, where the cases are projected to decline due to factors such as a decreasing population and other factors. The highest proportion of CLBP cases was reported in Spain among the EU4 countries, while the least number of cases was found in France.

The estimates show the Diagnosed Prevalent Cases of CLBP in Japan was found to be around 10 million in 2022, which is estimated to decrease by 2034 because of the decreasing country population.

The Gender-specific Diagnosed Prevalent Cases of CLBP in the 7MM were approximately 37 million for females and 30 million for males in 2022 and are expected to increase within the forecast period (2023-2034). The increased prevalence in females is likely due to a combination of factors, including psychological factors, female hormone fluctuations, and others.

As per the analysis, the Age-specific Diagnosed Prevalent Cases of CLBP based on age were categorized into 18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, and 70+ years. The higher number of cases (~7 million) was accounted for by the 70+ years age group in 2022 in the US.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Princeton Spine & Joint Center, Department of Anesthesiology, University of Michigan, University Hospital Giessen, Germany, University of Salerno, Italy and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

  • The report covers a segment of key events, an executive summary, descriptive overview of Chronic Lower Back Pain, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
  • The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
  • A detailed review of current challenges in establishing the diagnosis.

Chronic Lower Back Pain Report Insights

  • Patient Population
  • Country-wise Epidemiology Distribution
  • Prevalent Cases of CLBP
  • Diagnosed Prevalent Cases of CLBP
  • Gender-specific Diagnosed Prevalent Cases of CLBP
  • Age-specific Diagnosed Prevalent Cases of CLBP

Chronic Lower Back Pain Report Key Strengths

  • 12 years Forecast
  • The 7MM Coverage
  • Chronic Lower Back Pain Epidemiology Segmentation

Chronic Lower Back Pain Report Assessment

  • Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

  • What are the disease risk, burdens, and unmet needs of Chronic Lower Back Pain? What will be the growth opportunities across the 7MM concerning the patient population of Chronic Lower Back Pain?
  • What is the historical and forecasted Chronic Lower Back Pain patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
  • Why is the prevalent cases of CLBP in Japan lower than the US?
  • Which country has a high patient share for CLBP?

Reasons to Buy

  • Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • To understand the Chronic Lower Back Pain prevalence cases in varying geographies over the coming years.
  • A detailed overview of Gender and Age-specific diagnosed prevalence of CLBP.
  • To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
  • Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Chronic Lower Back Pain Epidemiology report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Chronic Lower Back Pain (CLBP) cases in 2022?

The highest cases of Chronic Lower Back Pain was found in the Germany among EU4 and the UK in 2022.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Chronic Lower Back Pain (CLBP) cases in 2022?

The highest cases of Chronic Lower Back Pain were found in the US among the 7MM in 2022.

Table of Contents

1. Key Insights2. Report Introduction
3. Chronic Lower Back Pain (CLBP) Epidemiology Overview
3.1. Patient Share (%) Distribution of CLBP in 2020
3.2. Patient Share (%) Distribution of CLBP in 2034
4. Epidemiology Methodology of CLBP5. Executive Summary of CLBP6. Key Events
7. Disease Background and Overview
7.1. Introduction
7.2. Symptoms
7.3. Etiology
7.4. Pathophysiology
7.5. Neurodegenerative Conditions Associated With CLBP
7.6. Biomarkers
7.7. Diagnosis
7.7.1. AAPT Diagnostic Criteria for CLBP
7.7.2. Test for CLAB diagnosis
7.7.3. Imaging Guidelines
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale: The 7MM
8.3. Total Prevalent Cases of CLBP in the 7MM
8.4. Total Diagnosed Prevalent Cases of CLBP in the 7MM
8.5. The United States
8.5.1. Total Prevalent Cases of CLBP in the United States
8.5.2. Total Diagnosed Prevalent Cases of CLBP in the United States
8.5.3. Gender-specific Diagnosed Prevalent Cases of CLBP in the United States
8.5.4. Age-specific Diagnosed Prevalent Cases of CLBP in the United States
8.6. EU4 and the UK
8.6.1. Germany
8.6.1.1. Total Prevalent Cases of CLBP in Germany
8.6.1.2. Total Diagnosed Prevalent Cases of CLBP in Germany
8.6.1.3. Gender-specific Diagnosed Prevalent Cases of CLBP in Germany
8.6.1.4. Age-specific Diagnosed Prevalent Cases of CLBP in Germany
8.6.2. France
8.6.2.1. Total Prevalent Cases of CLBP in France
8.6.2.2. Total Diagnosed Prevalent Cases of CLBP in France
8.6.2.3. Gender-specific Diagnosed Prevalent Cases of CLBP in France
8.6.2.4. Age-specific Diagnosed Prevalent Cases of CLBP in France
8.6.3. Italy
8.6.3.1. Total Prevalent Cases of CLBP in Italy
8.6.3.2. Total Diagnosed Prevalent Cases of CLBP in Italy
8.6.3.3. Gender-specific Diagnosed Prevalent Cases of CLBP in Italy
8.6.3.4. Age-specific Diagnosed Prevalent Cases of CLBP in Italy
8.6.4. Spain
8.6.4.1. Total Prevalent Cases of CLBP in Spain
8.6.4.2. Total Diagnosed Prevalent Cases of CLBP in Spain
8.6.4.3. Gender-specific Diagnosed Prevalent Cases of CLBP in Spain
8.6.4.4. Age-specific Diagnosed Prevalent Cases of CLBP in Spain
8.6.5. UK
8.6.5.1. Total Prevalent Cases of CLBP in the UK
8.6.5.2. Total Diagnosed Prevalent Cases of CLBP in the UK
8.6.5.3. Gender-specific Diagnosed Prevalent Cases of CLBP in the UK
8.6.5.4. Age-specific Diagnosed Prevalent Cases of CLBP in the UK
8.7. Japan
8.7.1. Total Prevalent Cases of CLBP in Japan
8.7.2. Total Diagnosed Prevalent Cases of CLBP in Japan
8.7.3. Gender-specific Diagnosed Prevalent Cases of CLBP in Japan
8.7.4. Age-specific Diagnosed Prevalent Cases of CLBP in Japan
9. Patient Journey10. Key Opinion Leaders’ Views
11. Appendix
11.1. Bibliography
11.2. Acronyms and Abbreviations
11.3. Report Methodology
12. Publisher Capabilities13. Disclaimer14. About the Publisher
List of Tables
Table 1: Summary of CLBP Epidemiology (2020-2034)
Table 2: Key Events
Table 3: Risk Factors for Occurrence and Chronicity of Low Back Pain
Table 4: Cause of Muscle Connective Tissue Fibrosis
Table 5: AAPT Diagnostic Criteria
Table 6: Clinical Evaluation
Table 7: Graded Chronic Pain Scale (GCPS)
Table 8: Total Prevalent Cases of CLBP in the 7MM in 000’s (2020-2034)
Table 9: Total Diagnosed Prevalent Cases of CLBP in the 7MM in 000’s (2020-2034)
Table 10: Total Prevalent Cases of CLBP in the US in ‘000’(2020-2034)
Table 11: Total Diagnosed Prevalent Cases of CLBP in the US in 000’s (2020-2034)
Table 12: Gender-specific Diagnosed Prevalent Cases of CLBP in the US in 000’s (2020-2034)
Table 13: Age-specific Diagnosed Prevalent Cases of CLBP in the US in 000’s (2020-2034)
Table 14: Total Prevalent Cases of CLBP in Germany (2020-2034)
Table 15: Total Prevalent Cases of CLBP in France (2020-2034)
Table 16: Total Prevalent Cases of CLBP in Italy (2020-2034)
Table 17: Total Prevalent Cases of CLBP in Spain (2020-2034)
Table 18: Total Prevalent Cases of CLBP in the UK (2020-2034)
Table 19: Total Prevalent Cases of CLBP in EU4 and the UK, in 000’s (2020-2034)
Table 20: Total Diagnosed Prevalent Cases of CLBP in Germany (2020-2034)
Table 21: Total Diagnosed Prevalent Cases of CLBP in France (2020-2034)
Table 22: Total Diagnosed Prevalent Cases of CLBP in Italy (2020-2034)
Table 23: Total Diagnosed Prevalent Cases of CLBP in Spain (2020-2034)
Table 24: Total Diagnosed Prevalent Cases of CLBP in the UK (2020-2034)
Table 25: Total Diagnosed Prevalent Cases of CLBP in EU4 and the UK in 000’s (2020-2034)
Table 26: Gender-specific Diagnosed Prevalent Cases of CLBP in Germany in 000’s (2020-2034)
Table 27: Gender-specific Diagnosed Prevalent Cases of CLBP in France in 000’s (2020-2034)
Table 28: Gender-specific Diagnosed Prevalent Cases of CLBP in Italy in 000’s (2020-2034)
Table 29: Gender-specific Diagnosed Prevalent Cases of CLBP in Spain in 000’s (2020-2034)
Table 30: Gender-specific Diagnosed Prevalent Cases of CLBP in the UK in 000’s (2020-2034)
Table 31: Gender-specific Diagnosed Prevalent Cases of CLBP in EU4 and the UK in 000’s (2020-2034)
Table 32: Age-specific Diagnosed Prevalent Cases of CLBP in Germany in 000’s (2020-2034)
Table 33: Age-specific Diagnosed Prevalent Cases of CLBP in France in 000’s (2020-2034)
Table 34: Age-specific Diagnosed Prevalent Cases of CLBP in Italy in 000’s (2020-2034)
Table 35: Age-specific Diagnosed Prevalent Cases of CLBP in Spain in 000’s (2020-2034)
Table 36: Age-specific Diagnosed Prevalent Cases of CLBP in the UK in 000’s (2020-2034)
Table 37: Age-specific Diagnosed Prevalent Cases of CLBP in EU4 and the UK in 000’s (2020-2034)
Table 38: Total Prevalent Population of CLBP in Japan in 000’s (2020-2034)
Table 39: Total Diagnosed Prevalent Cases of CLBP in Japan in 000’s (2020-2034)
Table 40: Gender-specific Diagnosed Prevalent Cases of CLBP in Japan in 000’s (2020-2034)
Table 41: Age-specific Diagnosed Prevalence of CLBP in Japan in 000’s (2020-2034)
List of Figures
Figure 1: Types of Lower Back Pain
Figure 2: Definitions of Chronic Lower Back Pain
Figure 3: Signs and Symptoms of CLBP
Figure 4: Pathophysiological Model for CLBP Linking Somatic and Behavioral Components
Figure 5: Relationship Describing Therapeutic Inventions and Pathogenic Mechanism
Figure 6: Types of Pain Involved in CLBP Mechanism
Figure 7: Total Prevalent Cases of CLBP in the 7MM (2020-2034)
Figure 8: Total Diagnosed Prevalent Cases of CLBP in the 7MM (2020-2034)
Figure 9: Total Prevalent Cases of CLBP in the US (2020-2034)
Figure 10: Total Diagnosed Prevalent Cases of CLBP in the US in 000’s (2020-2034)
Figure 11: Gender-specific Diagnosed Prevalent Cases of CLBP in the US in 000’s (2020-2034)
Figure 12: Age-specific Diagnosed Prevalent Cases of CLBP in the US in 000’s (2020-2034)
Figure 13: Total Prevalent Cases of CLBP in Germany in 000’s (2020-2034)
Figure 14: Total Prevalent Cases of CLBP in France in 000’s (2020-2034)
Figure 15: Total Prevalent Cases of CLBP in Italy in 000’s (2020-2034)
Figure 16: Total Prevalent Cases of CLBP in Spain in 000’s (2020-2034)
Figure 17: Total Prevalent Cases of CLBP in EU4 and the UK in 000’s (2020-2034)
Figure 18: Total Diagnosed Prevalent Cases of CLBP in Germany in 000’s (2020-2034)
Figure 19: Total Diagnosed Prevalent Cases of CLBP in France in 000’s (2020-2034)
Figure 20: Total Diagnosed Prevalent Cases of CLBP in Italy in 000’s (2020-2034)
Figure 21: Total Diagnosed Prevalent Cases of CLBP in Spain in 000’s (2020-2034)
Figure 22: Total Diagnosed Prevalent Cases of CLBP in EU4 and the UK in 000’s (2020-2034)
Figure 23: Gender-specific Diagnosed Prevalent Cases of CLBP in Germany in 000’s (2020-2034)
Figure 24: Gender-specific Diagnosed Prevalent Cases of CLBP in France in 000’s (2020-2034)
Figure 25: Gender-specific Diagnosed Prevalent Cases of CLBP in Italy in 000’s (2020-2034)
Figure 26: Gender-specific Diagnosed Prevalent Cases of CLBP in Spain in 000’s (2020-2034)
Figure 27: Gender-specific Diagnosed Prevalent Cases of CLBP in EU4 and the UK in 000’s (2020-2034)
Figure 28: Age-specific Diagnosed Prevalent Cases of CLBP in Germany in 000’s (2020-2034)
Figure 29: Age-specific Diagnosed Prevalent Cases of CLBP in France in 000’s (2020-2034)
Figure 30: Age-specific Diagnosed Prevalent Cases of CLBP in Italy in 000’s (2020-2034)
Figure 31: Age-specific Diagnosed Prevalent Cases of CLBP in Spain in 000’s (2020-2034)
Figure 32: Age-specific Diagnosed Prevalent Cases of CLBP in EU4 and the UK in 000’s (2020-2034)
Figure 33: Total Prevalent Cases of CLBP in Japan in 000’s (2020-2034)
Figure 34: Total Diagnosed Prevalent Cases of CLBP in Japan in 000’s (2020-2034)
Figure 35: Gender-specific Diagnosed Prevalent Cases of CLBP in Japan in 000’s (2020-2034)
Figure 36: Age-specific Diagnosed Prevalent Cases of CLBP in Japan in 000’s (2020-2034)
Figure 37: CLBP Patient Journey